Sensorion

Patients receiving chemotherapy
#Cancer treatment #Chemotherapy #Hearing Loss #Phase II trial #Sensorion

Drug could prevent chemotherapy-induced hearing loss

Biotechnology company Sensorion has enrolled the first patient in its Phase IIa Proof of Concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.  Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity,… Read More

#Cancer Research #News